Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Sensitive Subjects Exposed to Ragweed Pollen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Female subject of non-childbearing potential or of childbearing potential agreeing not to become pregnant during the study.~* Have had seasonal allergic rhinitis due to Ragweed for the last 2 consecutive years~* Subjects who obtain a minimum sum considering SAR related symptoms (mean value) as defined by protocol~Exclusion Criteria:~* Any clinically significant condition that might interfere with the treatment evaluation, both for efficacy and safety~* Have used forbidden concomitant medications as defined by the protocol

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (PBO) (Type: PLACEBO_COMPARATOR): A single dose of placebo was administered orally on Day 1.
- Levocetirizine (LCTZ) 2.5 mg (Type: EXPERIMENTAL): A single dose of 2.5 mg of LCTZ oral drops was administered orally on Day 1.
- Levocetirizine (LCTZ) 5 mg (Type: EXPERIMENTAL): A single dose of 5 mg of LCTZ oral tablet was administered orally on Day 1.
- Cetirizine (CTZ) 5 mg (Type: EXPERIMENTAL): A single dose of 5 mg of CTZ oral drops was administered orally on Day 1.
- Cetirizine (CTZ) 10 mg (Type: EXPERIMENTAL): A single dose of 10 mg of CTZ oral tablet was administered orally on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).